Paysign Q1 rev +23% to $10.1M, net loss narrows; Q2 guidance calls for continued growth

Paysign, Inc.

2023-Q1 EPS reported $0.00 revenue$10,143,290

Q1 2023 revenues $10.1M (+23% YoY); net loss $0.2M improved from $0.3M loss a year ago.
Adjusted EBITDA $0.7M (down 22% YoY); guided Q2 rev growth 15-20%, Adj. EBITDA growth 5-10%.
Added 10 plasma centers (total 439); launched 7 pharma copay programs (total 26); gross spend +31%.
Unrestricted cash $6.4M (down $3.3M from Dec 2022) due to AR build, capex, and $0.7M stock buyback.
Gross margin fell to 49.8% from 60.8% on higher third-party costs and mix shift toward lower-margin plasma.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Paysign, Inc. reported first quarter 2023 results: revenue $10.1 million, net income ($0.2) million, EPS ($0.00) per diluted share.

Period: first quarter 2023
Revenue: $10.1 million
Net income: ($0.2) million
EPS: ($0.00) per diluted share
Result: reported results

Exact text from the filing

First quarter total revenues of $10.1 million, up 23% from first quarter 2022 · First quarter net loss of ($0.2) million, or diluted loss per share of ($0.00)

View on SEC.gov

Browse all earnings releases →

Paysign, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-003122

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.